Adaptimmune Therapeutics Names William Betrand as Chief Operating Officer

Adaptimmune Therapeutics said Wednesday it has appointed William Betrand to the role of chief operating officer, effective immediately, succeeding Helen Tayton-Martin, who has been named chief business officer.

Bertrand will assume responsibility for a range of operational functions, including compliance, risk management, human resources and legal/IP, based at Adaptimmune’s U.S. headquarters in Philadelphia.

Tayton-Martin will now focus on optimizing the strategic and commercial opportunity, including all aspects of pipeline and technology assessment, strategic portfolio analysis, partnerships and commercial planning. She also retains responsibility for alliances including the strategic partnership with GSK.